# Prazosin and Cerebrospinal Fluid (CSF) Biomarkers in Mild Traumatic Brain Injury (mTBI)

> **NCT03221751** · PHASE4 · TERMINATED · sponsor: **VA Office of Research and Development** · enrollment: 9 (actual)

## Conditions studied

- Dementia

## Interventions

- **DRUG:** prazosin hydrochloride
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT03221751
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-01
- **Primary completion:** 2023-01-03
- **Final completion:** 2023-12-05
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** staffing issues and COVID
- **Last updated:** 2024-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03221751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03221751, "Prazosin and Cerebrospinal Fluid (CSF) Biomarkers in Mild Traumatic Brain Injury (mTBI)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03221751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*